IHH-Daiichi legal battle nears verdict on September 10

The legal war between healthcare giant IHH Healthcare Berhad and Japanese pharmaceutical firm Daiichi Sankyo is nearing a final countdown.

In a recent regulatory filing to the Malaysian and Singaporean stock exchanges, IHH confirmed that the Tokyo District Court has concluded all preparatory and oral proceedings regarding a massive damages claim filed by its subsidiary, Northern TK Venture Pte Ltd (NTK).

The court is scheduled to pronounce its judgment on September 10, a ruling that could have significant implications for both Asian corporates.



Also Read: Organon gives Sun Pharma scale and reach, but challenge lies in integration, execution

IHH is the parent company of India’s Fortis Healthcare Limited.

NTK is a company incorporated under the laws of Singapore and an indirect subsidiary of IHH Healthcare Berhad.

In May last year, NTK had announced on the stock exchanges in Malaysia and Singapore that it had filed an application with the Tokyo District Court to amend its ongoing claim for damages against Daiichi Sankyo Company, Limited, and had increased the damages claimed against Daiichi Sankyo by approximately tenfold.

As a result, the revised damages sought by NTK increased from the initial amount of JPY 20 billion to approximately JPY 200 billion.

IHH operates hospitals across Malaysia, Singapore, India, Turkey under brands including Parkway, Pantai.

NTK's claim at the Tokyo District Court for damages and other reliefs arises from alleged obstruction by Daiichi Sankyo of NTK’s efforts to complete its open offers to acquire shares in Fortis Healthcare Limited and its step-down subsidiary, Fortis Malar Hospitals Limited.

In November 2025, IHH announced the completion of the open offers.

The September 10 ruling represents the end of a long period of uncertainty.